Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Works matching IS 11707690 AND DT 2022 AND VI 40 AND IP 1
Results: 24
1
2
PharmacoEconomics: Supplement.
- Published in:
- 2022
- Publication type:
- Announcement
3
Correction to: Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
4
Importance of Patient Involvement in the Value Assessment Process: On the Way Towards Personalised Treatments.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
5
Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 1, p. 103, doi. 10.1007/s40273-021-01118-2
- By:
- Publication type:
- Article
6
Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 1, p. 39, doi. 10.1007/s40273-021-01115-5
- By:
- Publication type:
- Article
7
Correction to: Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA).
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
8
Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 1, p. 11, doi. 10.1007/s40273-021-01105-7
- By:
- Publication type:
- Article
9
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA).
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 1, p. 69, doi. 10.1007/s40273-021-01095-6
- By:
- Publication type:
- Article
10
Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 1, p. 91, doi. 10.1007/s40273-021-01092-9
- By:
- Publication type:
- Article
11
In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
12
Acknowledgement to Referees.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 1, p. 1, doi. 10.1007/s40273-021-01126-2
- Publication type:
- Article
13
Correction to: A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
14
CHEERS to 30 Years of PharmacoEconomics.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
15
Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 1, p. 45, doi. 10.1007/s40273-021-01094-7
- By:
- Publication type:
- Article
16
Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 1, p. 31, doi. 10.1007/s40273-021-01087-6
- By:
- Publication type:
- Article
17
Authors' Response to "Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery".
- Published in:
- 2022
- By:
- Publication type:
- Letter
18
Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery.
- Published in:
- 2022
- By:
- Publication type:
- Letter
19
Biased Survival Predictions When Appraising Health Technologies in Heterogeneous Populations.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 1, p. 109, doi. 10.1007/s40273-021-01082-x
- By:
- Publication type:
- Article
20
The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 1, p. 91, doi. 10.1007/s40273-021-01081-y
- By:
- Publication type:
- Article
21
Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 1, p. 77, doi. 10.1007/s40273-021-01078-7
- By:
- Publication type:
- Article
22
An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 1, p. 121, doi. 10.1007/s40273-021-01077-8
- By:
- Publication type:
- Article
23
A General Public Study on Preferences and Welfare Impacts of Antimicrobial Resistance in the United Kingdom.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 1, p. 65, doi. 10.1007/s40273-021-01076-9
- By:
- Publication type:
- Article
24
The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 1, p. 13, doi. 10.1007/s40273-021-01070-1
- By:
- Publication type:
- Article